First cure for younger patients with Parkinson's?

A newly developed drug molecule could pave the way for treatments to prevent Parkinson’s disease in younger patients, according to recent research. “We are excited about this compound because it presents the potential to develop the first cure for Parkinson’s disease, at least for a subset of patients,” said Kalle Gehring, the study's lead author and a professor in the Department of Biochemistry at McGill University. Gehring also holds the Canada Research Chair in Structural Studies of Neurodegenerative Diseases. While Parkinson’s disease symptoms, such as slowed movements, tremors, and balance problems, typically appear in people in their 60s, about 5–10% of cases are diagnosed before the age of 40. Parkinson’s is a degenerative disorder affecting over 100,000 Canadians, the researchers noted. The study explored how a molecule, developed by biotech company Biogen, can reactivate a key protein known as parkin. This protein plays a vital role in keeping brain cells healthy by clearing out damaged mitochondria, which are the cell's energy producers. In some younger patients, mutations in parkin disrupt this process, leading to the accumulation of damaged mitochondria, a factor contributing to Parkinson’s disease. Using advanced technology at the Canadian Light Source (CLS) at the University of Saskatchewan, the researchers discovered that the Biogen compound restores parkin’s function by binding it to a natural activator present in cells, effectively reactivating its cleaning role. Published in Nature Communications, the findings provide a foundation for designing personalized treatments for younger patients with specific parkin mutations, according to the study’s authors. “The goal is to eventually find compounds that can treat Parkinson’s disease more broadly,” said Gehring, emphasizing that it will be up to Biogen to apply these findings in future drug development. “As Canada’s population ages and treatments for other diseases improve, neurodegenerative diseases like Parkinson’s will become a significant health concern,” he added. The research was a collaborative effort between McGill groups led by Professor Jean-François Trempe from the Department of Pharmacology & Therapeutics and Professor Edward Fon at the Montreal Neurological Institute and Hospital. The study received funding from the Michael J. Fox Foundation, the Canadian Institutes of Health Research, and the Canada Research Chairs program.